Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


Oliena Studio

Stroke and language recovery: 9000+ videos

EspañolItalianoSarduEnglish | PDF+


  Colorectal Neoplasms

  Free Subscription


Articles published in Ann Oncol

Retrieve available abstracts of 76 articles:
HTML format
Text format



Single Articles


    August 2019
  1. NYAMUNDANDA G, Fontana E, Sadanandam A
    Is the tumour microenvironment a critical prognostic factor in early-stage colorectal cancer?
    Ann Oncol. 2019 Aug 29. pii: 5556307. doi: 10.1093.
    PubMed     Text format    


  2. DIENSTMANN R, Villacampa G, Sveen A, Mason MJ, et al
    Relative contribution of clinicopathological variables, genomic markers, transcriptomic subtyping and microenvironment features for outcome prediction in stage II/III colorectal cancer.
    Ann Oncol. 2019 Aug 27. pii: 5555302. doi: 10.1093.
    PubMed     Text format     Abstract available


  3. SIRAVEGNA G, Bardelli A
    Failure is not final: ctDNA-guided rechallenge therapy in colorectal cancer.
    Ann Oncol. 2019 Aug 13. pii: 5548994. doi: 10.1093.
    PubMed     Text format    


    July 2019
  4. TAIEB J, Shi Q, Pederson L, Alberts S, et al
    Prognosis of microsatellite instability and/or mismatch repair deficiency stage III colon cancer patients after disease recurrence following adjuvant treatment: results of an accent pooled analysis of 7 studies.
    Ann Oncol. 2019 Jul 3. pii: 5527754. doi: 10.1093.
    PubMed     Text format     Abstract available


    June 2019
  5. SOUGLAKOS J, Boukovinas I, Kakolyris S, Xynogalos S, et al
    Three versus six months adjuvant FOLFOX or CAPOX for high risk stage II and stage III colon cancer patients: the efficacy results of Hellenic Oncology Research Group (HORG) participation to the International Duration Evaluation of Adjuvant chemotherap
    Ann Oncol. 2019 Jun 22. pii: 5522015. doi: 10.1093.
    PubMed     Text format     Abstract available


    May 2019
  6. HAMFJORD J, Guren TK, Dajani O, Johansen JS, et al
    Total circulating cell-free DNA as a prognostic biomarker in metastatic colorectal cancer prior to first-line oxaliplatin-based chemotherapy.
    Ann Oncol. 2019 May 2. pii: 5482571. doi: 10.1093.
    PubMed     Text format     Abstract available


    April 2019
  7. SCHROCK AB, Ouyang C, Sandhu J, Sokol E, et al
    Tumor mutational burden is predictive of response to immune checkpoint inhibitors in MSI-high metastatic colorectal cancer.
    Ann Oncol. 2019 Apr 30. pii: 5482063. doi: 10.1093.
    PubMed     Text format     Abstract available


    March 2019
  8. SANTOS C, Azuara D, Vieitez JM, Paez D, et al
    Phase II study of high-sensitivity genotyping of KRAS, NRAS, BRAF and PIK3CA to ultra-select metastatic colorectal cancer patients for panitumumab plus FOLFIRI: the ULTRA trial.
    Ann Oncol. 2019 Mar 6. pii: 5370172. doi: 10.1093.
    PubMed     Text format     Abstract available


    February 2019
  9. FONTANA E, Eason K, Cervantes A, Salazar R, et al
    Context Matters - Consensus Molecular Subtypes of Colorectal Cancer as Biomarkers for Clinical Trials.
    Ann Oncol. 2019 Feb 23. pii: 5364014. doi: 10.1093.
    PubMed     Text format     Abstract available


  10. GUNTER MJ, Alhomoud S, Arnold M, Brenner H, et al
    Meeting Report from the joint IARC-NCI international cancer seminar series: a focus on colorectal cancer.
    Ann Oncol. 2019 Feb 5. pii: 5307027. doi: 10.1093.
    PubMed     Text format     Abstract available


  11. SINGH AV
    21PEvaluation of magnetic nanoparticle of irinotecan for personalized treatment of colorectal cancer.
    Ann Oncol. 2019;30.
    PubMed     Text format    


  12. CAVIC M, Vidosavljevic M, Radulovic S, Grahovac J, et al
    20PNischarin expression in colon cancer.
    Ann Oncol. 2019;30.
    PubMed     Text format    


  13. LEE CL, Toomey S, Farrelly A, Hennessy B, et al
    19PPreclinical drug testing and clinical trial planning of palbociclib (CDK4/6 inhibitor) drug combination with a PI3K or MAPK inhibitor for colorectal cancer (CRC).
    Ann Oncol. 2019;30.
    PubMed     Text format    


    January 2019
  14. VIDAL J, Bellosillo B, Santos Vivas C, Garcia-Alfonso P, et al
    Ultra-selection of metastatic colorectal cancer patients using Next Generation Sequencing to improve clinical efficacy of anti-EGFR therapy.
    Ann Oncol. 2019 Jan 23. pii: 5299439. doi: 10.1093.
    PubMed     Text format     Abstract available


    December 2018
  15. SHITARA K, Yamanaka T, Denda T, Tsuji Y, et al
    REVERCE: A Randomized Phase II Study of Regorafenib Followed by Cetuximab Versus the Reverse Sequence for Previously Treated Metastatic Colorectal Cancer Patients.
    Ann Oncol. 2018 Dec 3. pii: 5227619. doi: 10.1093.
    PubMed     Text format     Abstract available


    November 2018
  16. SIRAVEGNA G, Bardelli A
    Failure is not final: ctDNA-guided rechallenge therapy in colorectal cancer.
    Ann Oncol. 2018 Nov 26. pii: 5209692. doi: 10.1093.
    PubMed     Text format    


    October 2018
  17. WANG Y, Jones JC, Kipp BR, Grothey A, et al
    Activity of EGFR Antibody in Non-V600 BRAF Mutant Metastatic Colorectal Cancer.
    Ann Oncol. 2018 Oct 26. pii: 5145082. doi: 10.1093.
    PubMed     Text format    


    September 2018
  18. MOOI JK, Wirapati P, Asher R, Lee CK, et al
    The prognostic impact of Consensus Molecular Subtypes (CMS) and its predictive effects for bevacizumab benefit in metastatic colorectal cancer: molecular analysis of the AGITG MAX clinical trial.
    Ann Oncol. 2018 Sep 21. pii: 5104878. doi: 10.1093.
    PubMed     Text format     Abstract available


    July 2018
  19. MAURI G, Bencardino K, Sartore-Bianchi A, Siena S, et al
    Toxicity of oxaliplatin rechallenge in metastatic colorectal cancer.
    Ann Oncol. 2018 Jul 28. pii: 5061139. doi: 10.1093.
    PubMed     Text format    


  20. VAN CUTSEM E, Yoshino T, Lenz HJ, Lonardi S, et al
    Nintedanib for the treatment of patients with refractory metastatic colorectal cancer (LUME-Colon 1): a phase III, international, randomized, placebo-controlled study.
    Ann Oncol. 2018 Jul 13. pii: 5053583. doi: 10.1093.
    PubMed     Text format     Abstract available


  21. OVERMAN MJ, Adam L, Raghav K, Wang J, et al
    Phase II study of nab-paclitaxel in refractory small bowel adenocarcinoma and CpG island methylator phenotype (CIMP)-high colorectal cancer.
    Ann Oncol. 2018 Jul 3. pii: 5048416. doi: 10.1093.
    PubMed     Text format    


    June 2018
  22. SARTORE-BIANCHI A, Siena S
    The right chance for temozolomide in metastatic colorectal cancer?
    Ann Oncol. 2018 Jun 25. pii: 5044274. doi: 10.1093.
    PubMed     Text format    


  23. SOBRERO A, Douillard JY
    Reply to the Letter to the Editor: "The hard road to patient-centered care: 3 or 6 months of adjuvant chemotherapy for patients with stage III colon cancer?" By P. Trendsz et al.
    Ann Oncol. 2018 Jun 15. pii: 5038506. doi: 10.1093.
    PubMed     Text format    


  24. TAN RYC, Camat MD, Ng M, Lim TH, et al
    HER2 positive rates are enriched amongst colorectal cancer brain metastases: a study amongst 1920 consecutive patients.
    Ann Oncol. 2018 Jun 3. pii: 5001837. doi: 10.1093.
    PubMed     Text format    


    May 2018
  25. MORANO F, Corallo S, Niger M, Barault L, et al
    Temozolomide and irinotecan (TEMIRI regimen) as salvage treatment of irinotecan-sensitive advanced colorectal cancer patients bearing MGMT methylation.
    Ann Oncol. 2018 May 31. pii: 5026003. doi: 10.1093.
    PubMed     Text format     Abstract available


  26. TRENSZ P, Calvel L, Kurtz JE
    The hard road to patient-centered care: 3 or 6 months of adjuvant chemotherapy for patients with stage III colon cancer?
    Ann Oncol. 2018 May 22. pii: 5001429. doi: 10.1093.
    PubMed     Text format    


    April 2018
  27. APARICIO T, Bouche O, Taieb J, Maillard E, et al
    Bevacizumab+chemotherapy versus chemotherapy alone in elderly patients with untreated metastatic colorectal cancer: a randomized phase II trial-PRODIGE 20 study results.
    Ann Oncol. 2018 Apr 30. pii: 4990353. doi: 10.1093.
    PubMed     Text format    


  28. CREMOLINI C, Antoniotti C, Lonardi S, Bergamo F, et al
    Primary tumor sidedness and benefit from FOLFOXIRI plus bevacizumab as initial therapy for metastatic colorectal cancer. Retrospective analysis of the TRIBE trial by GONO.
    Ann Oncol. 2018 Apr 20. pii: 4979452. doi: 10.1093.
    PubMed     Text format     Abstract available


  29. CREMOLINI C, Antoniotti C, Lonardi S, Bergamo F, et al
    Primary Tumor Sidedness and Benefit from FOLFOXIRI plus Bevacizumab as Initial Therapy for Metastatic Colorectal Cancer.
    Ann Oncol. 2018 Apr 20. pii: 4979452. doi: 10.1093.
    PubMed     Text format     Abstract available


  30. SANTOS C, Sanz-Pamplona R, Salazar R
    RET-fusions: a novel paradigm in colorectal cancer.
    Ann Oncol. 2018 Apr 10. pii: 4965879. doi: 10.1093.
    PubMed     Text format    


  31. SIENA S, Sartore-Bianchi A, Marsoni S, Hurwitz HI, et al
    Targeting the human epidermal growth factor receptor 2 (HER2) oncogene in colorectal cancer.
    Ann Oncol. 2018 Apr 6. pii: 4962457. doi: 10.1093.
    PubMed     Text format     Abstract available


  32. MASUISHI T, Taniguchi H, Sugiyama K, Kato K, et al
    Eribulin in BRAF V600E mutant metastatic colorectal cancer: Case series and potential rationale.
    Ann Oncol. 2018 Apr 4. pii: 4959907. doi: 10.1093.
    PubMed     Text format    


    March 2018
  33. MALVEZZI M, Carioli G, Bertuccio P, Boffetta P, et al
    European cancer mortality predictions for the year 2018 with focus on colorectal cancer.
    Ann Oncol. 2018 Mar 19. pii: 4935197. doi: 10.1093.
    PubMed     Text format     Abstract available


  34. MONTAGUT C, Tsui DW, Diaz LA Jr.
    Detection of somatic RAS mutations in circulating tumor DNA from metastatic colorectal cancer patients: are we ready for clinical use?
    Ann Oncol. 2018 Mar 14. pii: 4937227. doi: 10.1093.
    PubMed     Text format    


  35. SMEBY J, Sveen A, Merok MA, Danielsen SA, et al
    CMS-dependent prognostic impact of KRAS and BRAFV600E mutations in primary colorectal cancer.
    Ann Oncol. 2018 Mar 5. pii: 4922418. doi: 10.1093.
    PubMed     Text format     Abstract available


  36. VIVANCOS A, Elez E, Salazar R
    Circulating cell-free DNA as predictor of treatment failure after neoadjuvant chemoradiotherapy before surgery in patients with locally advanced rectal cancer: is it ready for primetime?
    Ann Oncol. 2018;29:532-534.
    PubMed     Text format    


  37. SCHOU JV, Larsen FO, Sorensen BS, Abrantes R, et al
    Circulating cell-free DNA as predictor of treatment failure after neoadjuvant chemo-radiotherapy before surgery in patients with locally advanced rectal cancer.
    Ann Oncol. 2018;29:610-615.
    PubMed     Text format     Abstract available


    February 2018
  38. ARNOLD D, Prager GW, Quintela A, Stein A, et al
    Beyond Second-Line Therapy in Patients With Metastatic Colorectal Cancer: A Systematic Review.
    Ann Oncol. 2018 Feb 14. pii: 4857261. doi: 10.1093.
    PubMed     Text format     Abstract available


  39. BACHET JB, Bouche O, Taieb J, Dubreuil O, et al
    RAS mutation analysis in circulating tumor DNA from patients with metastatic colorectal cancer: the AGEO RASANC prospective multicenter study.
    Ann Oncol. 2018 Feb 9. pii: 4846852. doi: 10.1093.
    PubMed     Text format     Abstract available


  40. CARR PR, Alwers E, Bienert S, Weberpals J, et al
    Lifestyle factors and risk of sporadic colorectal cancer by microsatellite instability status: A systematic review and meta-analyses.
    Ann Oncol. 2018 Feb 9. pii: 4846850. doi: 10.1093.
    PubMed     Text format     Abstract available


  41. SOBRERO A, Grothey A, Iveson T, Labianca R, et al
    The hard road to data interpretation: three or six months of adjuvant chemotherapy for patients with stage III colon cancer?
    Ann Oncol. 2018 Feb 9. pii: 4846853. doi: 10.1093.
    PubMed     Text format     Abstract available


  42. WILLIS JA, Vilar E
    Pharmacogenomics: time to rethink its role in precision medicine.
    Ann Oncol. 2018;29:293-295.
    PubMed     Text format    


    January 2018
  43. SOBHANI I, Itti E, Luciani A, Baumgaertner I, et al
    Colorectal Cancer (CRC) Monitoring by Six-Monthly 18FDG-PET/CT: An Open-Label Multicentre Randomised Trial.
    Ann Oncol. 2018 Jan 22. pii: 4819113. doi: 10.1093.
    PubMed     Text format     Abstract available


  44. CARMELIET P, Li X, Treps L, Conradi LC, et al
    RAISEing VEGF-D's importance as predictive biomarker for ramucirumab in metastatic colorectal cancer patients.
    Ann Oncol. 2018 Jan 19. pii: 4817343. doi: 10.1093.
    PubMed     Text format    


  45. PARK JH, McMillan DC
    Outcome in colorectal cancer - tumour, stroma and so much more.
    Ann Oncol. 2018 Jan 8. pii: 4792956. doi: 10.1093.
    PubMed     Text format    


  46. DELL'AQUILA E, Cremolini C, Zeppola T, Lonardi S, et al
    Prognostic and predictive role of neutrophil/lymphocytes ratio in metastatic colorectal cancer: a retrospective analysis of the TRIBE study by GONO.
    Ann Oncol. 2018 Jan 8. pii: 4793700. doi: 10.1093.
    PubMed     Text format     Abstract available


    December 2017
  47. KHOSROW-KHAVAR F, Yin H, Barkun A, Bouganim N, et al
    Aromatase Inhibitors and the Risk of Colorectal Cancer in Post-Menopausal Women with Breast Cancer.
    Ann Oncol. 2017 Dec 27. pii: 4779926. doi: 10.1093.
    PubMed     Text format     Abstract available


  48. DANIELSEN HE, Hveem TS, Domingo E, Pradhan M, et al
    Prognostic markers for colorectal cancer; estimating ploidy and stroma.
    Ann Oncol. 2017 Dec 27. pii: 4779924. doi: 10.1093.
    PubMed     Text format     Abstract available


  49. YAMADA Y, Denda T, Gamoh M, Iwanaga I, et al
    S-1 and irinotecan plus bevacizumab versus mFOLFOX6 or CapeOX plus bevacizumab as first-line treatment in patients with metastatic colorectal cancer (TRICOLORE): a randomized, open-label, phase 3, non-inferiority trial.
    Ann Oncol. 2017 Dec 27. pii: 4779925. doi: 10.1093.
    PubMed     Text format     Abstract available


  50. GONG J, Tian J, Lou J, Wang X, et al
    A polymorphic MYC response element in KBTBD11 influences colorectal cancer risk, especially in interaction with a MYC regulated SNP rs6983267.
    Ann Oncol. 2017 Dec 18. pii: 4756051. doi: 10.1093.
    PubMed     Text format     Abstract available


  51. ORDONEZ-ME JM, Walter V, Schottker B, Jenab M, et al
    Impact of prediagnostic smoking and smoking cessation on colorectal cancer prognosis: a meta-analysis of individual patient data from cohorts within the CHANCES consortium.
    Ann Oncol. 2017 Dec 13. pii: 4735153. doi: 10.1093.
    PubMed     Text format     Abstract available


  52. TABERNERO J, Hozak RR, Yoshino T, Cohn AL, et al
    Analysis of Angiogenesis Biomarkers for Ramucirumab Efficacy in Patients with Metastatic Colorectal Cancer from RAISE, a Global, Randomized, Double-Blind, Phase III Study.
    Ann Oncol. 2017 Dec 7. pii: 4708229. doi: 10.1093.
    PubMed     Text format     Abstract available


    November 2017
  53. YOSHINO T, Arnold D, Taniguchi H, Pentheroudakis G, et al
    Pan-Asian adapted ESMO consensus guidelines for the management of patients with metastatic colorectal cancer; A JSMO - ESMO initiative endorsed by CSCO, KACO, MOS, SSO and TOS.
    Ann Oncol. 2017 Nov 16. doi: 10.1093.
    PubMed     Text format     Abstract available


  54. ABAD A, Martinez-Balibrea E, Vieitez JM, Orduna VA, et al
    Genotype-based selection of treatment for patients with advanced colorectal cancer (SETICC): a pharmacogenetic-based randomized phase II trial.
    Ann Oncol. 2017 Nov 14. doi: 10.1093.
    PubMed     Text format     Abstract available


  55. DIENSTMANN R, Guinney J
    Reply to the letter to the editor 'Including lynch syndrome in personalized prognostication and follow-up of stage II and III colon cancer' by Sciallero et al.
    Ann Oncol. 2017;28:2889-2890.
    PubMed     Text format    


    October 2017
  56. OVERMAN M, Adam L, Raghav K, Wang J, et al
    Phase II study of nab-paclitaxel in refractory small bowel adenocarcinoma and CpG island methylator phenotype (CIMP)-high colorectal cancer.
    Ann Oncol. 2017 Oct 23. doi: 10.1093.
    PubMed     Text format     Abstract available


  57. TARAZONA N, Cervantes A
    Liquid biopsy: another tool towards tailored therapy in colorectal cancer.
    Ann Oncol. 2017 Oct 10. doi: 10.1093.
    PubMed     Text format    


  58. SCIALLERO S, Battistuzzi L, Varesco L
    Including Lynch syndrome in personalized prognostication and follow-up of stage II and III colon cancer.
    Ann Oncol. 2017;28:2620-2621.
    PubMed     Text format    


  59. CASADEI GARDINI A, Valgiusti M, Passardi A, Frassineti GL, et al
    Treatment of squamous cell carcinoma of the anal canal (SCCA): a new era?
    Ann Oncol. 2017;28:2620.
    PubMed     Text format    


    September 2017
  60. APARICIO T, Bouche O, Taieb J, Maillard E, et al
    Bevacizumab + chemotherapy versus chemotherapy alone in elderly patients with untreated metastatic colorectal cancer: a randomized phase II trial - PRODIGE 20 study results.
    Ann Oncol. 2017 Sep 28. doi: 10.1093.
    PubMed     Text format     Abstract available


  61. CREMOLINI C, Morano F, Moretto R, Berenato R, et al
    Negative hyper-selection of metastatic colorectal cancer patients for anti-EGFR monoclonal antibodies: the PRESSING case-control study.
    Ann Oncol. 2017 Sep 25. doi: 10.1093.
    PubMed     Text format     Abstract available


  62. GARCIA-FONCILLAS J, Alba E, Aranda E, Diaz-Rubio E, et al
    Incorporating BEAMing technology as a liquid biopsy into clinical practice for the management of colorectal cancer patients: an expert taskforce review.
    Ann Oncol. 2017 Sep 4. doi: 10.1093.
    PubMed     Text format     Abstract available


  63. SIENA S, Sartore-Bianchi A, Garcia-Carbonero R, Karthaus M, et al
    Dynamic Molecular Analysis and Clinical Correlates of Tumor Evolution Within a Phase 2 Trial of Panitumumab-Based Therapy in Metastatic Colorectal Cancer.
    Ann Oncol. 2017 Sep 4. doi: 10.1093.
    PubMed     Text format     Abstract available


  64. SOBRERO A, Damiani A
    Maintenance therapy in advanced colorectal cancer, yes or no? Ask the laboratory.
    Ann Oncol. 2017;28:2043-2044.
    PubMed     Text format    


  65. WEI Q, Ye Z, Zhong X, Li L, et al
    Multiregion whole-exome sequencing of matched primary and metastatic tumors revealed genomic heterogeneity and suggested polyclonal seeding in colorectal cancer metastasis.
    Ann Oncol. 2017;28:2135-2141.
    PubMed     Text format     Abstract available


  66. GOEY KKH, Elias SG, van Tinteren H, Lacle MM, et al
    Maintenance treatment with capecitabine and bevacizumab versus observation in metastatic colorectal cancer: updated results and molecular subgroup analyses of the phase 3 CAIRO3 study.
    Ann Oncol. 2017;28:2128-2134.
    PubMed     Text format     Abstract available


    August 2017
  67. NORMANNO N, Esposito Abate R, Lambiase M, Forgione L, et al
    RAS testing of liquid biopsy correlates with the outcome of metastatic colorectal cancer patients treated with first-line FOLFIRI plus cetuximab in the CAPRI-GOIM trial.
    Ann Oncol. 2017 Aug 7. doi: 10.1093.
    PubMed     Text format     Abstract available


  68. BERGER MD, Stintzing S, Heinemann V, Yang D, et al
    Impact of genetic variations in the MAPK signaling pathway on outcome in metastatic colorectal cancer patients treated with first-line FOLFIRI and bevacizumab: data from FIRE-3 and TRIBE trials.
    Ann Oncol. 2017 Aug 2. doi: 10.1093.
    PubMed     Text format     Abstract available


    July 2017
  69. SANZ-GARCIA E, Argiles G, Elez E, Tabernero J, et al
    BRAF mutant Colorectal Cancer: prognosis, treatment and new perspectives.
    Ann Oncol. 2017 Jul 24. doi: 10.1093.
    PubMed     Text format     Abstract available


    June 2017
  70. SCHLESINGER S, Aleksandrova K, Abar L, Vieria AR, et al
    Adult weight gain and colorectal adenomas-a systematic review and meta-analysis.
    Ann Oncol. 2017;28:1217-1229.
    PubMed     Text format     Abstract available


    May 2017
  71. OTT PA, Piha-Paul SA, Munster P, Pishvaian MJ, et al
    Safety and antitumor activity of the anti-PD-1 antibody pembrolizumab in patients with recurrent carcinoma of the anal canal.
    Ann Oncol. 2017;28:1036-1041.
    PubMed     Text format     Abstract available


    March 2017
  72. ROMBOUTS AJM, Hugen N, Elferink MAG, Feuth T, et al
    Incidence of second tumors after treatment with or without radiation for rectal cancer.
    Ann Oncol. 2017;28:535-540.
    PubMed     Text format     Abstract available


    February 2017
  73. PATEL UB, Brown G, Machado I, Santos-Cores J, et al
    MRI assessment and outcomes in patients receiving neoadjuvant chemotherapy only for primary rectal cancer: long-term results from the GEMCAD 0801 trial.
    Ann Oncol. 2017;28:344-353.
    PubMed     Text format     Abstract available


  74. YANG TO, Cairns BJ, Reeves GK, Green J, et al
    Cancer risk among 21st century blood transfusion recipients.
    Ann Oncol. 2017;28:393-399.
    PubMed     Text format     Abstract available


  75. GLYNNE-JONES R
    Adding extra dimensions in rectal cancer theory.
    Ann Oncol. 2017;28:198-200.
    PubMed     Text format    


    January 2017
  76. POWELL MA
    Immunohistochemistry to determine mismatch repair-deficiency in endometrial cancer: the appropriate standard.
    Ann Oncol. 2017;28:9-10.
    PubMed     Text format    


Thank you for your interest in scientific medicine.


AMEDEO Colorectal Neoplasms is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: